Tumor mutational burden as a prognostic biomarker for survival and quality of life in metastatic colorectal cancer patients receiving anti-PD-1/PD-L1 immunotherapy
The aim of this study was to assess the prognostic value of tumor mutational burden (TMB) as a biomarker for metastatic colorectal cancer (mCRC) in patients receiving immunotherapy-containing regimens. This retrospective cohort study analyzed 221 patients with mCRC. From January 1, 2020 to December 31, 2021, patients d...